or via email
Comparison of Next-Generation Incretin/Agonist Peptides
*This information has not been approved by the FDA and is not endorsed by Grey Axis Research. It is provided for informational purposes only for researchers in the field of Incretin/Agonist Peptides.*
This document provides a side-by-side comparison of Mazdutide, Survodutide, Retatrutide, and Tirzepatide — four leading GLP-1–based investigational and approved therapies.
|
Peptide |
Type / Targets |
Developer |
Trial Status (2025) |
Main Effects |
Reported Weight Loss |
Notes |
|
Mazdutide |
Dual agonist: |
Innovent Biologics & Eli Lilly (China) |
Phase III in China |
Appetite suppression + ↑ energy expenditure |
~15–20% in Phase II |
China-focused; rival to global GLP-1 drugs |
|
Survodutide |
Dual agonist: |
Boehringer Ingelheim & Zealand Pharma |
Phase II/III (obesity, MASH/NASH) |
Appetite suppression + fat oxidation, liver protection |
Up to ~19% at 46 weeks |
Strong candidate for obesity + liver disease (MASH) |
|
Retatrutide |
Triple agonist: |
Eli Lilly |
Phase II/III |
Appetite suppression + ↑ energy expenditure + improved glucose metabolism |
~24% at 48 weeks |
Highest weight loss to date; first triple agonist |
|
Tirzepatide |
Dual agonist: |
Eli Lilly (Mounjaro®, Zepbound®) |
FDA-approved (diabetes & obesity) |
Appetite suppression + insulin sensitivity |
~20–22% in obesity trials |
First-in-class dual agonist; already on market |
Key Takeaways:
– Tirzepatide is FDA-approved and commercially available.
– Retatrutide demonstrates the highest weight loss (~24%).
– Mazdutide and Survodutide, both GLP-1 + Glucagon dual agonists, show strong promise for obesity and liver-related conditions.
– All are under active development except Tirzepatide, which is already marketed.